Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of PF-07321332/Ritonavir and Ritonavir on Midazolam PK in Healthy Participants
NCT05032950Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2021
- Primary completion
- Dec 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration of Midazolam, Area Under the Plasma Concentration-time Profile From Time 0 Extrapolated to Infinity and 1 more. Started Sep 2021; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05032950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05032950.